Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
Go back to Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.57 +0.03 (0.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.54 | 52 Week High | $0.04 | |||
| Open | $4.60 | 52 Week Low | $0.00 | |||
| Day High | $4.65 | P/E | N/A | |||
| Day Low | $4.52 | EPS | $-0.09 | |||
| Volume | 910,021 | |||||
